An additional clinical trial for RYANODEX for exertional heat stroke

Trial Profile

An additional clinical trial for RYANODEX for exertional heat stroke

Planning
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs Dantrolene (Primary)
  • Indications Heat stroke
  • Focus Registrational; Therapeutic Use
  • Sponsors Eagle Pharmaceuticals
  • Most Recent Events

    • 10 May 2018 According to an Eagle Pharmaceuticals media release, this trial is planned for August 17-23, 2018 during the Hajj pilgrimage.
    • 01 Mar 2018 New trial record
    • 26 Feb 2018 According to an Eagle Pharmaceuticals media release, this trial is conducted as per the FDA suggestion in complete Response Letter regarding New Drug Application for RYANODEX for the treatment of exertional heat stroke (EHS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top